Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions

Pacelli, A.; Greenman, J.; Cawthorne, C.; Smith, G.

Abstract

The role of cyclooxygenase (COX)-2 as a driving force in early tumourigenesis and the current interest in the combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent need to establish clinically relevant diagnostic tests for COX-2 expression. Molecular imaging using small-molecule probes radiolabelled for both positron emission tomography (PET) and single photon emission computed tomography (SPECT) offers the potential to meet this need, providing a minimally invasive readout for the whole disease burden. This review summarises current approaches to the radiolabelling of small-molecule COX-2 inhibitors and their analogues for PET and SPECT imaging, and gives an overview of their biological evaluation and likely success of clinical application. © 2013 John Wiley & Sons, Ltd.

Citation

Pacelli, A., Greenman, J., Cawthorne, C., & Smith, G. (2014). Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions. Journal of Labelled Compounds and Radiopharmaceuticals, 57(4), 317-322. https://doi.org/10.1002/jlcr.3160

• Journal Article Type: Article
• Acceptance Date: Oct 29, 2013
• Online Publication Date: Dec 18, 2013
• Publication Date: 2014-04
• Deposit Date: Feb 25, 2016
• Publicly Available Date: Feb 25, 2016
• Journal: Journal of labelled compounds and radiopharmaceuticals
• Print ISSN: 0362-4803
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 57
• Issue: 4
• Pages: 317-322
• DOI: https://doi.org/10.1002/jlcr.3160
• Keywords: Coxib; Indole; Imidazole; [11C]-methylation; PET; SPECT; COX-2; Prostaglandin; Cancer; Imaging biomarker
• Public URL: https://hull-repository.worktribe.com/output/411536
• Publisher URL: http://onlinelibrary.wiley.com/doi/10.1002/jlcr.3160/abstract
• Additional Information: This is the author's accepted manuscript of an article published in Journal of labelled compounds and radiopharmaceuticals, 2014, v.57 issue 4.
• Contract Date: Feb 25, 2016